CL2014003241A1 - Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar. - Google Patents

Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar.

Info

Publication number
CL2014003241A1
CL2014003241A1 CL2014003241A CL2014003241A CL2014003241A1 CL 2014003241 A1 CL2014003241 A1 CL 2014003241A1 CL 2014003241 A CL2014003241 A CL 2014003241A CL 2014003241 A CL2014003241 A CL 2014003241A CL 2014003241 A1 CL2014003241 A1 CL 2014003241A1
Authority
CL
Chile
Prior art keywords
lpar
antagonists
pulmonary fibrosis
acid receptor
lysophosphatidic acid
Prior art date
Application number
CL2014003241A
Other languages
English (en)
Inventor
Stephen Deems Gabriel
Yimin Qian
Matthew Michael Hamilton
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003241(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2014003241A1 publication Critical patent/CL2014003241A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2014003241A 2012-06-20 2014-11-28 Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar. CL2014003241A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261661953P 2012-06-20 2012-06-20

Publications (1)

Publication Number Publication Date
CL2014003241A1 true CL2014003241A1 (es) 2015-03-20

Family

ID=48628669

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003241A CL2014003241A1 (es) 2012-06-20 2014-11-28 Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar.

Country Status (22)

Country Link
US (1) US20150133512A1 (es)
EP (1) EP2864301A1 (es)
JP (1) JP2015520203A (es)
KR (1) KR20150011389A (es)
CN (1) CN104395299A (es)
AU (1) AU2013279513A1 (es)
BR (1) BR112014030674A2 (es)
CA (1) CA2869564A1 (es)
CL (1) CL2014003241A1 (es)
CO (1) CO7131357A2 (es)
EA (1) EA201492281A1 (es)
HK (1) HK1206339A1 (es)
IL (1) IL236087A0 (es)
IN (1) IN2014DN09352A (es)
MA (1) MA37762B1 (es)
MX (1) MX2014014711A (es)
PE (1) PE20142305A1 (es)
PH (1) PH12014502363A1 (es)
SG (1) SG11201407228PA (es)
UA (1) UA110310C2 (es)
WO (1) WO2013189865A1 (es)
ZA (1) ZA201408167B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2744807A4 (en) 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS
TW201437200A (zh) * 2013-01-15 2014-10-01 Intermune Inc 溶血磷脂酸受體拮抗劑
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
AU2015281021B9 (en) 2014-06-27 2019-03-28 Ube Corporation Salt of halogen-substituted heterocyclic compound
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
CN107721984A (zh) * 2017-11-07 2018-02-23 大连理工大学 一种新型5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑的制备方法
CN107827829A (zh) * 2017-11-07 2018-03-23 大连理工大学 5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑在水相及生物介质中的制备方法
EP3728222B1 (en) 2017-12-19 2023-03-29 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as lpa antagonists
EP3728210A1 (en) 2017-12-19 2020-10-28 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
JP7369125B2 (ja) * 2017-12-19 2023-10-25 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのイソキサゾールｏ－架橋カルバモイルシクロヘキシル酸
CN112074515A (zh) 2017-12-19 2020-12-11 百时美施贵宝公司 作为lpa拮抗剂的环己基酸异噁唑唑类
TW202017918A (zh) 2017-12-19 2020-05-16 美商必治妥美雅史谷比公司 作為lpa拮抗劑之環己基酸三唑吖
BR112020011953A2 (pt) 2017-12-19 2020-11-17 Bristol-Myers Squibb Company ácidos carbamoil ciclo-hexílicos n-ligados a pirazol como antagonistas de lpa
BR112020012177A2 (pt) 2017-12-19 2020-11-24 Bristol-Myers Squibb Company azóis triazóis do ácido ciclo-hexílico como antagonistas de lpa
US11261174B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists
WO2019126086A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as lpa antagonists
JP7212047B2 (ja) 2017-12-19 2023-01-24 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
CN111434653A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 三氮唑类化合物及其制备方法与用途
EP4058144A1 (en) 2019-11-15 2022-09-21 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
IL298082A (en) 2020-06-03 2023-01-01 Gilead Sciences Inc lpa receptor antagonists and uses thereof
KR20240005892A (ko) 2021-05-11 2024-01-12 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
CN115745848A (zh) * 2022-12-07 2023-03-07 上海优合生物科技有限公司 一种氨基胍的加工合成工艺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159550A2 (en) * 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
BR112013014019A2 (pt) * 2010-12-07 2016-09-13 Amira Pharmaceuticals Inc antagonistas do receptor do ácido lisofosfatídico e seus usos
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
EP2744807A4 (en) * 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS
BR112014030685A2 (pt) * 2012-06-20 2017-06-27 Hoffmann La Roche compostos de n-alquiltriazol como antagonistas de lpar

Also Published As

Publication number Publication date
WO2013189865A1 (en) 2013-12-27
MA37762B1 (fr) 2018-04-30
IN2014DN09352A (es) 2015-07-17
CA2869564A1 (en) 2013-12-27
ZA201408167B (en) 2015-12-23
MA37762A1 (fr) 2017-07-31
EA201492281A1 (ru) 2015-04-30
IL236087A0 (en) 2015-02-01
HK1206339A1 (en) 2016-01-08
MX2014014711A (es) 2015-03-04
SG11201407228PA (en) 2014-12-30
PH12014502363A1 (en) 2015-01-12
AU2013279513A1 (en) 2014-10-16
US20150133512A1 (en) 2015-05-14
BR112014030674A2 (pt) 2017-06-27
CN104395299A (zh) 2015-03-04
KR20150011389A (ko) 2015-01-30
PE20142305A1 (es) 2015-01-16
JP2015520203A (ja) 2015-07-16
UA110310C2 (uk) 2015-12-10
CO7131357A2 (es) 2014-12-01
EP2864301A1 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
CL2014003241A1 (es) Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar.
CL2014003243A1 (es) Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra fibrosis pulmonar.
CL2014003242A1 (es) Compuestos de pirazol sustituidos como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra la fibrosis pulmonar.
HK1210601A1 (en) Stable aqueous formulations of adalimumab
DK2882850T3 (da) System for preparation of adipose-derived stem cells
CO7061086A2 (es) Combinaciones de compuestos activos
CL2014003031A1 (es) Compuestos derivados de uracilo sustituidos biciclicamente; procedimiento de preparacion; composicion farmaceutica; uso para tratar y/o prevenir insuficiencia cardiaca, hipertension pulmonar, epoc, asma, nefropatia, entre otras.
HK1209749A1 (en) Beta amino acid derivatives as integrin antagonists
DK2869854T3 (da) Sammensætning omfattende ectoin eller hydroxyectoin som en aktiv substans til at fremme regenereringen af beskadiget kropsvæv
CO6950497A2 (es) Compuestos de 1,2,5-oxadiazol sustituidos y su uso como herbicidas
CL2015001399A1 (es) Composiciones detergentes acuosas de estructura polimérica.
BR112013012452A2 (pt) uso de dispersões aquosas como primers
CR20140263A (es) Composicion herbicida que contiene acido de 4-amino-3-cloro-6-(-4-cloro-2-fluor-3-metoxifenil) piridina-2-carboxilico, o los derivados del mismo y fluroxipir, o los derivados del mismo
SMT201500296B (it) Antagonisti del recettore trpm8
HK1207633A1 (en) Benzimidazol.es as cns active agents cns
CR20140343A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
HK1225712A1 (zh) 作爲溶血磷脂酸受體拮抗劑的酰胺衍生物
BR112014010153A2 (pt) formulação esporicida, lenço e lenço umedecido
PL2836580T3 (pl) Mikrofibrylarna celuloza jako substancja czynna zdolna do odrywania brudu
ZA201500979B (en) Electrochemical generation of chlorinated urea derivatives
FR3027522B1 (fr) Composition poreuse chargee en principe actif
BR112013009640A2 (pt) derivados de tetrahidroquinolina usados como ativadores de ampk
FR2989199B1 (fr) Adaptateur electriquement actif
BR112015003828A2 (pt) uso de um hidrolisado de caseína como um agente anti-herpético
UA23380S (uk) Елементи корпуса циліндричного силосу (комплект)